Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrEP-GAHT Interactions in TGW
NCT04760691Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Mar 2021
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (5 arms), sponsored by Johns Hopkins University. Primary endpoints: Maximum Tenofovir Plasma Concentration, Calculated Plasma TFV Area Under the Concentration-Time Curve and 2 more. Started Mar 2021; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04760691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04760691.